{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:06:00Z","timestamp":1788671160971,"version":"build-2803163510"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Identification of mutations in histones in a number of human neoplasms and developmental syndromes represents the most compelling evidence to date for a causal role of epigenetic perturbations in human disease. In most cases, these mutations have gain of function properties that cause deviation from normal developmental processes leading to embryo defects and\/or neoplastic transformation. These exciting discoveries represent a step-change in our understanding of the role of chromatin (dys)regulation in development and disease. However, the mechanisms of action of oncogenic histone mutations (oncohistones) remain only partially understood. Here, we critically assess existing literature on oncohistones focussing mainly on bone neoplasms. We show how it is possible to draw parallels with some of the cell-autonomous mechanisms of action described in paediatric brain cancer, although the functions of oncohistones in bone tumours remain under-investigated. In this respect, it is becoming clear that histone mutations targeting the same residues display, at least in part, tissue-specific oncogenic mechanisms. Furthermore, it is emerging that cancer cells carrying oncohistones can modify the surrounding microenvironment to support growth and\/or alter differentiation trajectories. A better understanding of oncohistone function in different neoplasms provide potential for identification of signalling that could be targeted therapeutically. Finally, we discuss some of the main concepts and future directions in this research area, while also drawing possible connections and parallels with other cancer epigenetic mechanisms.<\/jats:p>","DOI":"10.1038\/s41418-023-01227-9","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T17:02:11Z","timestamp":1697130131000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["(B)On(e)-cohistones and the epigenetic alterations at the root of bone cancer"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-8116","authenticated-orcid":false,"given":"Paolo","family":"Salomoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2832-1303","authenticated-orcid":false,"given":"Adrienne M.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9397-4925","authenticated-orcid":false,"given":"Lucia","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"1227_CR1","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1126\/science.1063127","volume":"293","author":"T Jenuwein","year":"2001","unstructured":"Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074\u201380.","journal-title":"Science"},{"key":"1227_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17:487\u2013500.","journal-title":"Nat Rev Genet"},{"key":"1227_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41576-019-0105-7","volume":"20","author":"PB Talbert","year":"2019","unstructured":"Talbert PB, Meers MP, Henikoff S. Old cogs, new tricks: the evolution of gene expression in a chromatin context. Nat Rev Genet. 2019;20:283\u201397.","journal-title":"Nat Rev Genet"},{"key":"1227_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrg.2016.13","volume":"17","author":"AP Feinberg","year":"2016","unstructured":"Feinberg AP, Koldobskiy MA, G\u00f6nd\u00f6r A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17:284\u201399.","journal-title":"Nat Rev Genet"},{"key":"1227_CR5","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1126\/science.1230184","volume":"340","author":"ML Suv\u00e0","year":"2013","unstructured":"Suv\u00e0 ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;340:1567\u201370.","journal-title":"Science"},{"key":"1227_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482:226\u201331.","journal-title":"Nature"},{"key":"1227_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","volume":"44","author":"G Wu","year":"2012","unstructured":"Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44:251\u20133.","journal-title":"Nat Genet"},{"key":"1227_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","volume":"124","author":"DA Khuong-Quang","year":"2012","unstructured":"Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012;124:439\u201347.","journal-title":"Acta Neuropathol"},{"key":"1227_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-019-1038-1","volume":"567","author":"BA Nacev","year":"2019","unstructured":"Nacev BA, Feng L, Bagert JD, Lemiesz AE, Gao JJ, Soshnev AA, et al. The expanding landscape of \u2018oncohistone\u2019 mutations in human cancers. Nature. 2019;567:473\u20138.","journal-title":"Nature"},{"key":"1227_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-021-01057-x","volume":"13","author":"S Amatori","year":"2021","unstructured":"Amatori S, Tavolaro S, Gambardella S, Fanelli M. The dark side of histones: genomic organization and role of oncohistones in cancer. Clin Epigenetics. 2021;13:1\u201321.","journal-title":"Clin Epigenetics"},{"key":"1227_CR11","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1101\/gad.309013.117","volume":"31","author":"F Mohammad","year":"2017","unstructured":"Mohammad F, Helin K. Oncohistones: drivers of pediatric cancers. Genes Dev. 2017;31:2313\u201324.","journal-title":"Genes Dev"},{"key":"1227_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-cancerbio-030617-050143","volume":"2","author":"K Funato","year":"2018","unstructured":"Funato K, Tabar V. Histone mutations in cancer. Annu Rev Cancer Biol. 2018;2:337\u201351.","journal-title":"Annu Rev Cancer Biol"},{"key":"1227_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ccell.2017.09.014","volume":"32","author":"M Pathania","year":"2017","unstructured":"Pathania M, De Jay N, Maestro N, Harutyunyan AS, Nitarska J, Pahlavan P, et al. H3.3 K27M cooperates with Trp53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas. Cancer Cell. 2017;32:684\u2013700.","journal-title":"Cancer Cell"},{"key":"1227_CR14","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/ng.2814","volume":"45","author":"S Behjati","year":"2013","unstructured":"Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479\u201382.","journal-title":"Nat Genet"},{"key":"1227_CR15","doi-asserted-by":"crossref","unstructured":"Andrade AF, Chen CCL, Jabado N. Oncohistones in brain tumors: the soil and seed. Trends Cancer. 2023;9:444\u201355.","DOI":"10.1016\/j.trecan.2023.02.003"},{"key":"1227_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41589-021-00738-1","volume":"17","author":"JD Bagert","year":"2021","unstructured":"Bagert JD, Mitchener MM, Patriotis AL, Dul BE, Wojcik F, Nacev BA, et al. Oncohistone mutations enhance chromatin remodeling and alter cell fates. Nat Chem Biol. 2021;17:403\u201311.","journal-title":"Nat Chem Biol"},{"key":"1227_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201911131","volume":"12","author":"TG Gr\u00fcnewald","year":"2020","unstructured":"Gr\u00fcnewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre\u2010Aranaz F, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020;12:1\u201333.","journal-title":"EMBO Mol Med"},{"key":"1227_CR18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41568-020-0288-4","volume":"20","author":"BA Nacev","year":"2020","unstructured":"Nacev BA, Jones KB, Intlekofer AM, Yu JSE, Allis CD, Tap WD, et al. The epigenomics of sarcoma. Nat Rev Cancer. 2020;20:608\u201323.","journal-title":"Nat Rev Cancer"},{"key":"1227_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/gcc.22699","volume":"58","author":"D Baumhoer","year":"2019","unstructured":"Baumhoer D, Amary F, Flanagan AM. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosom Cancer. 2019;58:88\u201399.","journal-title":"Genes Chromosom Cancer"},{"key":"1227_CR20","unstructured":"Editorial Board. WHO classification of soft tissue and bone tumours. France: IARC, Lyon; 2020."},{"key":"1227_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/path.5537","volume":"252","author":"MW Fittall","year":"2020","unstructured":"Fittall MW, Lyskj\u00e6r I, Ellery P, Lombard P, Ijaz J, Strobl AC, et al. Drivers underpinning the malignant transformation of giant cell tumour of bone. J Pathol. 2020;252:433\u201340.","journal-title":"J Pathol"},{"key":"1227_CR22","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1097\/PAS.0000000000000512","volume":"39","author":"AHG Cleven","year":"2015","unstructured":"Cleven AHG, H\u00f6cker S, Briaire-De Bruijn I, Szuhai K, Cleton-Jansen AM, Bov\u00e9e JVMG. Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015;39:1576\u201383.","journal-title":"Am J Surg Pathol"},{"key":"1227_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/modpathol.2016.212","volume":"30","author":"T Kervarrec","year":"2017","unstructured":"Kervarrec T, Collin C, Larousserie F, Bouvier C, Aubert S, Gomez-Brouchet A, et al. H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach. Mod Pathol. 2017;30:393\u2013406.","journal-title":"Mod Pathol"},{"key":"1227_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/cjp2.13","volume":"1","author":"N Presneau","year":"2015","unstructured":"Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1:113\u201323.","journal-title":"J Pathol Clin Res"},{"key":"1227_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0378-1119(03)00609-7","volume":"312","author":"D Frank","year":"2003","unstructured":"Frank D, Doenecke D, Albig W. Differential expression of human replacement and cell cycle dependent H3 histone genes. Gene. 2003;312:135\u201343.","journal-title":"Gene"},{"key":"1227_CR26","first-page":"699","volume":"41","author":"LA L\u00f3pez-Fern\u00e1ndez","year":"1997","unstructured":"L\u00f3pez-Fern\u00e1ndez LA, L\u00f3pez-Ala\u00f1\u00f3n DM, Casta\u00f1eda V, Krimer DB, Del Mazo J. Developmental expression of H3.3A variant histone mRNA in mouse. Int J Dev Biol. 1997;41:699\u2013703.","journal-title":"Int J Dev Biol"},{"key":"1227_CR27","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.aac7272","volume":"352","author":"C Lu","year":"2016","unstructured":"Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, et al. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science. 2016;352:844\u20139.","journal-title":"Science"},{"key":"1227_CR28","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1126\/science.aae0065","volume":"352","author":"D Fang","year":"2016","unstructured":"Fang D, Gan H, Lee JH, Han J, Wang Z, Riester SM, et al. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science. 2016;352:1344\u20138.","journal-title":"Science"},{"key":"1227_CR29","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1101\/gad.284323.116","volume":"30","author":"S Yang","year":"2016","unstructured":"Yang S, Zheng X, Lu C, Li GM, Allis CD, Li H. Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase. Genes Dev. 2016;30:1611\u20136.","journal-title":"Genes Dev"},{"key":"1227_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1126\/science.1232245","volume":"340","author":"PW Lewis","year":"2013","unstructured":"Lewis PW, M\u00fcller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340:857\u201361.","journal-title":"Science"},{"key":"1227_CR31","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.1016\/j.molcel.2021.10.008","volume":"81","author":"A Chaouch","year":"2021","unstructured":"Chaouch A, Berlandi J, Chen CCL, Frey F, Badini S, Harutyunyan AS, et al. Histone H3.3 K27M and K36M mutations de-repress transposable elements through perturbation of antagonistic chromatin marks. Mol Cell. 2021;81:4876\u20134890.e7.","journal-title":"Mol Cell"},{"key":"1227_CR32","doi-asserted-by":"publisher","first-page":"9598","DOI":"10.1073\/pnas.1806355115","volume":"115","author":"J Fang","year":"2018","unstructured":"Fang J, Huang Y, Mao G, Yang S, Rennert G, Gu L, et al. Cancer-driving H3G34V\/R\/D mutations block H3K36 methylation and H3K36me3-MutS\u03b1 interaction. Proc Natl Acad Sci USA. 2018;115:9598\u2013603.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1227_CR33","doi-asserted-by":"publisher","first-page":"27354","DOI":"10.1073\/pnas.2006076117","volume":"117","author":"SU Jain","year":"2020","unstructured":"Jain SU, Khazaei S, Marchione DM, Lundgren SM, Wang X, Weinberg DN, et al. Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression. Proc Natl Acad Sci USA. 2020;117:27354\u201364.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1227_CR34","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jmb.2018.04.014","volume":"430","author":"L Shi","year":"2018","unstructured":"Shi L, Shi J, Shi X, Li W, Wen H. Histone H3.3 G34 mutations alter histone H3K36 and H3K27 methylation in cis. J Mol Biol. 2018;430:1562\u20135.","journal-title":"J Mol Biol"},{"key":"1227_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-13887-y","volume":"7","author":"J Lim","year":"2017","unstructured":"Lim J, Park JH, Baude A, Yoo Y, Lee YK, Schmidt CR, et al. The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing. Sci Rep. 2017;7:1\u201314.","journal-title":"Sci Rep"},{"key":"1227_CR36","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/2159-8290.CD-20-0461","volume":"10","author":"S Khazaei","year":"2020","unstructured":"Khazaei S, De Jay N, Deshmukh S, Hendrikse LD, Jawhar W, Chen CCL, et al. H3.3 G34W promotes growth and impedes differentiation of osteoblast-like mesenchymal progenitors in giant cell tumor of bone. Cancer Discov. 2020;10:1968\u201387.","journal-title":"Cancer Discov"},{"key":"1227_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"1227_CR38","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/febs.15963","volume":"289","author":"S Deshmukh","year":"2022","unstructured":"Deshmukh S, Ptack A, Krug B, Jabado N. Oncohistones: a roadmap to stalled development. FEBS J. 2022;289:1315\u201328.","journal-title":"FEBS J"},{"key":"1227_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2019.02.001","volume":"448","author":"J Fellenberg","year":"2019","unstructured":"Fellenberg J, S\u00e4hr H, Mancarella D, Plass C, Lindroth AM, Westhauser F, et al. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells. Cancer Lett. 2019;448:61\u20139.","journal-title":"Cancer Lett"},{"key":"1227_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18955-y","volume":"11","author":"P Lutsik","year":"2020","unstructured":"Lutsik P, Baude A, Mancarella D, \u00d6z S, K\u00fchn A, Toth R, et al. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone. Nat Commun. 2020;11:1\u201337.","journal-title":"Nat Commun"},{"key":"1227_CR41","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1038\/s41418-022-01031-x","volume":"29","author":"L Cottone","year":"2022","unstructured":"Cottone L, Ligammari L, Lee HM, Knowles HJ, Henderson S, Bianco S, et al. Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone. Cell Death Differ. 2022;29:2459\u201371.","journal-title":"Cell Death Differ"},{"key":"1227_CR42","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1227_CR43","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"1227_CR44","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1007\/s00018-021-03798-7","volume":"78","author":"JM Gonzalez-Meljem","year":"2021","unstructured":"Gonzalez-Meljem JM, Martinez-Barbera JP. Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis. Cell Mol Life Sci. 2021;78:4521\u201344.","journal-title":"Cell Mol Life Sci"},{"key":"1227_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13205119","volume":"13","author":"RG Forsyth","year":"2021","unstructured":"Forsyth RG, Kren\u00e1cs T, Athanasou N, Hogendoorn PCW. Cell biology of giant cell tumour of bone: Crosstalk between m\/wt nucleosome H3.3, telomeres and osteoclastogenesis. Cancers (Basel). 2021;13:1\u201318.","journal-title":"Cancers (Basel)"},{"key":"1227_CR46","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","volume":"11","author":"D Thomas","year":"2010","unstructured":"Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11:275\u201380.","journal-title":"Lancet Oncol"},{"key":"1227_CR47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s13277-015-3094-y","volume":"36","author":"PF Wu","year":"2015","unstructured":"Wu PF, Tang JY, Li KH. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects. Tumor Biol. 2015;36:495\u2013501.","journal-title":"Tumor Biol"},{"key":"1227_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-04161-1","volume":"12","author":"Y He","year":"2021","unstructured":"He Y, Cheng D, Lian C, Liu Y, Luo W, Wang Y, et al. Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone. Cell Death Dis. 2021;12:1\u201310.","journal-title":"Cell Death Dis"},{"key":"1227_CR49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1158\/2159-8290.CD-12-0426","volume":"3","author":"L Bjerke","year":"2013","unstructured":"Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 2013;3:512\u20139.","journal-title":"Cancer Discov"},{"key":"1227_CR50","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1101\/gad.246561.114","volume":"28","author":"Z Cheng","year":"2014","unstructured":"Cheng Z, Cheung P, Kuo AJ, Yukl ET, Wilmot CM, Gozani O, et al. A molecular threading mechanism underlies Jumonji lysine demethylase KDM2A regulation of methylated H3K36. Genes Dev. 2014;28:1758\u201371.","journal-title":"Genes Dev"},{"key":"1227_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05607-5","volume":"9","author":"HPJ Voon","year":"2018","unstructured":"Voon HPJ, Udugama M, Lin W, Hii L, Law RHP, Steer DL, et al. Inhibition of a K9\/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma. Nat Commun. 2018;9:3142.","journal-title":"Nat Commun"},{"key":"1227_CR52","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","volume":"22","author":"D Sturm","year":"2012","unstructured":"Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones DTW, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22:425\u201337.","journal-title":"Cancer Cell"},{"key":"1227_CR53","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.cell.2023.02.023","volume":"186","author":"S Khazaei","year":"2023","unstructured":"Khazaei S, Chen CCL, Andrade AF, Kabir N, Azarafshar P, Morcos SM, et al. Single substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegeneration. Cell. 2023;186:1162\u20131178.e20.","journal-title":"Cell"},{"key":"1227_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.65369","volume":"10","author":"BR Lowe","year":"2021","unstructured":"Lowe BR, Yadav RK, Henry RA, Schreiner P, Matsuda A, Fernandez AG, et al. Surprising phenotypic diversity of cancer-associated mutations of gly 34 in the histone h3 tail. Elife. 2021;10:1\u201330.","journal-title":"Elife"},{"key":"1227_CR55","doi-asserted-by":"publisher","first-page":"eaau5935","DOI":"10.1126\/sciadv.aau5935","volume":"4","author":"JM Stafford","year":"2018","unstructured":"Stafford JM, Lee CH, Voigt P, Descostes N, Saldana-Meyer R, Yu JR, et al. Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma. Sci Adv. 2018;4:eaau5935.","journal-title":"Sci Adv"},{"key":"1227_CR56","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.molcel.2020.09.028","volume":"80","author":"SU Jain","year":"2020","unstructured":"Jain SU, Rashoff AQ, Krabbenhoft SD, Hoelper D, Do TJ, Gibson TJ, et al. H3 K27M and EZHIP impede H3K27-methylation spreading by inhibiting allosterically stimulated PRC2. Mol Cell. 2020;80:726\u2013735.e7.","journal-title":"Mol Cell"},{"key":"1227_CR57","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/nar\/gkac800","volume":"51","author":"LRZ Cohen","year":"2022","unstructured":"Cohen LRZ, Kaffe B, Deri E, Leibson C, Nissim-Rafinia M, Maman M, et al. PRC2-independent actions of H3.3K27M in embryonic stem cell differentiation. Nucleic Acids Res. 2022;51:1662\u201373.","journal-title":"Nucleic Acids Res"},{"key":"1227_CR58","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2020.11.012","volume":"183","author":"Chen CCL","year":"2020","unstructured":"Chen CCL, Deshmukh S, Jessa S, Hadjadj D, Lisi V, Andrade AF, et al. Histone H3.3G34-mutant interneuron progenitors co-opt PDGFRA for gliomagenesis. Cell. 2020;183:1617\u20131633.e22.","journal-title":"Cell"},{"key":"1227_CR59","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3109\/00313020903257749","volume":"41","author":"I Sulzbacher","year":"2009","unstructured":"Sulzbacher I, Dominkus M, Pichlhofer B, Mazal PR. Expression of platelet-derived growth factor-alpha receptor and c-kit in giant cell tumours of bone. Pathology. 2009;41:630\u20133.","journal-title":"Pathology"},{"key":"1227_CR60","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.stem.2021.01.016","volume":"28","author":"RB Bressan","year":"2021","unstructured":"Bressan RB, Southgate B, Ferguson KM, Blin C, Grant V, Alfazema N, et al. Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants. Cell Stem Cell. 2021;28:877\u2013893.e9.","journal-title":"Cell Stem Cell"},{"key":"1227_CR61","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41588-022-01205-w","volume":"54","author":"S Jessa","year":"2022","unstructured":"Jessa S, Mohammadnia A, Harutyunyan AS, Hulswit M, Varadharajan S, Lakkis H, et al. K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas. Nat Genet. 2022;54:1865\u201380.","journal-title":"Nat Genet"},{"key":"1227_CR62","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41588-019-0531-7","volume":"51","author":"S Jessa","year":"2019","unstructured":"Jessa S, Blanchet-Cohen A, Krug B, Vladoiu M, Coutelier M, Faury D, et al. Stalled developmental programs at the root of pediatric brain tumors. Nat Genet. 2019;51:1702\u201313.","journal-title":"Nat Genet"},{"key":"1227_CR63","doi-asserted-by":"publisher","first-page":"e154229","DOI":"10.1172\/JCI154229","volume":"132","author":"S Haase","year":"2022","unstructured":"Haase S, Banerjee K, Mujeeb AA, Hartlage CS, N\u00fa\u00f1ez FM, N\u00fa\u00f1ez FJ, et al. H3.3-G34 mutations impair DNA repair and promote cGAS\/STING-mediated immune responses in pediatric high-grade glioma models. J Clin Invest. 2022;132:e154229.","journal-title":"J Clin Invest"},{"key":"1227_CR64","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.jmb.2016.11.019","volume":"429","author":"L Shi","year":"2017","unstructured":"Shi L, Wen H, Shi X. The histone variant H3.3 in transcriptional regulation and human disease. J Mol Biol. 2017;429:1934\u201345.","journal-title":"J Mol Biol"},{"key":"1227_CR65","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00381-020-04933-8","volume":"37","author":"S Minasi","year":"2021","unstructured":"Minasi S, Baldi C, Gianno F, Antonelli M, Pietsch T, Massimino M, et al. Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma. Childs Nerv Syst. 2021;37:809\u201318.","journal-title":"Childs Nerv Syst"},{"key":"1227_CR66","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/path.2301","volume":"214","author":"R Forsyth","year":"2008","unstructured":"Forsyth R, De Boeck G, Bekaert S, De Meyer T, Taminiau A, Uyttendaele D, et al. Telomere biology in giant cell tumour of bone. J Pathol. 2008;214:555\u201363.","journal-title":"J Pathol"},{"key":"1227_CR67","first-page":"7489","volume":"15","author":"X Ren","year":"2018","unstructured":"Ren X, Tu C, Tang Z, Ma R, Li Z. Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas. Oncol Lett. 2018;15:7489\u201396.","journal-title":"Oncol Lett"},{"key":"1227_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.151583","volume":"7","author":"SB DeWitt","year":"2022","unstructured":"DeWitt SB, Plumlee SH, Brighton HE, Sivaraj D, Martz EJ, Zand M, et al. Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-\u03baB signaling and integrin binding. JCI Insight. 2022;7:1\u201319.","journal-title":"JCI Insight"},{"key":"1227_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.202215859","volume":"14","author":"Nonneville","year":"2022","unstructured":"Nonneville, De A, Guille A, Finetti P, Noble JR, Churikov D, et al. TOP 3 A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT. EMBO Mol Med. 2022;14:1\u201322.","journal-title":"EMBO Mol Med"},{"key":"1227_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22543-z","volume":"12","author":"M Udugama","year":"2021","unstructured":"Udugama M, Hii L, Garvie A, Cervini M, Vinod B, Chan FL, et al. Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas. Nat Commun. 2021;12:1\u201311.","journal-title":"Nat Commun"},{"key":"1227_CR71","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ccell.2019.04.004","volume":"35","author":"B Krug","year":"2019","unstructured":"Krug B, De Jay N, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, et al. Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas. Cancer Cell. 2019;35:782\u201397.","journal-title":"Cancer Cell"},{"key":"1227_CR72","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41556-021-00774-y","volume":"23","author":"JP Gerber","year":"2021","unstructured":"Gerber JP, Russ J, Chandrasekar V, Offermann N, Lee H, Spear S, et al. Aberrant chromatin landscape following loss of the H3.3 chaperone Daxx in haematopoietic precursors leads to Pu.1-mediated neutrophilia and inflammation. Nat Cell Biol. 2021;23:1224\u201339.","journal-title":"Nat Cell Biol"},{"key":"1227_CR73","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.stem.2015.07.022","volume":"17","author":"Q He","year":"2015","unstructured":"He Q, Kim H, Huang R, Lu W, Tang M, Shi F, et al. The Daxx\/Atrx complex protects tandem repetitive elements during DNA hypomethylation by promoting H3K9 trimethylation. Cell Stem Cell. 2015;17:273\u201386.","journal-title":"Cell Stem Cell"},{"key":"1227_CR74","doi-asserted-by":"publisher","first-page":"7734","DOI":"10.1093\/nar\/gkz634","volume":"47","author":"I Mahmud","year":"2019","unstructured":"Mahmud I, Liao D. DAXX in cancer: phenomena, processes, mechanisms and regulation. Nucleic Acids Res. 2019;47:7734\u201352.","journal-title":"Nucleic Acids Res"},{"key":"1227_CR75","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.tibs.2013.06.011","volume":"38","author":"D Clynes","year":"2013","unstructured":"Clynes D, Higgs DR, Gibbons RJ. The chromatin remodeller ATRX: a repeat offender in human disease. Trends Biochem Sci. 2013;38:461\u20136.","journal-title":"Trends Biochem Sci"},{"key":"1227_CR76","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/path.2913","volume":"224","author":"MF Amary","year":"2011","unstructured":"Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334\u201343.","journal-title":"J Pathol"},{"key":"1227_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-022-01084-0","volume":"14","author":"W Cross","year":"2022","unstructured":"Cross W, Lyskj\u00e6r I, Lesluyes T, Hargreaves S, Strobl AC, Davies C, et al. A genetic model for central chondrosarcoma evolution correlates with patient outcome. Genome Med. 2022;14:1\u201312.","journal-title":"Genome Med"},{"key":"1227_CR78","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/ng.994","volume":"43","author":"MF Amary","year":"2011","unstructured":"Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011;43:1262\u20135.","journal-title":"Nat Genet"},{"key":"1227_CR79","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021;18:645\u201361.","journal-title":"Nat Rev Clin Oncol"},{"key":"1227_CR80","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","volume":"34","author":"MS Waitkus","year":"2018","unstructured":"Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell. 2018;34:186\u201395.","journal-title":"Cancer Cell"},{"key":"1227_CR81","doi-asserted-by":"publisher","first-page":"100469","DOI":"10.1016\/j.xcrm.2021.100469","volume":"2","author":"IC Hvinden","year":"2021","unstructured":"Hvinden IC, Cadoux-Hudson T, Schofield CJ, McCullagh JSO. Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations. Cell Rep. Med. 2021;2:100469.","journal-title":"Cell Rep. Med"},{"key":"1227_CR82","doi-asserted-by":"publisher","first-page":"e20200924","DOI":"10.1084\/jem.20200924","volume":"218","author":"L Stuani","year":"2021","unstructured":"Stuani L, Sabatier M, Saland E, Cognet G, Poupin N, Bosc C, et al. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med. 2021;218:e20200924.","journal-title":"J Exp Med"},{"key":"1227_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-021-00247-8","volume":"9","author":"S Pathmanapan","year":"2021","unstructured":"Pathmanapan S, Ilkayeva O, Martin JT, Loe AKH, Zhang H, Zhang G, et al. Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes. Cancer Metab. 2021;9:1\u201314.","journal-title":"Cancer Metab"},{"key":"1227_CR84","first-page":"1","volume":"10","author":"Y Jin","year":"2015","unstructured":"Jin Y, Elalaf H, Watanabe M, Tamaki S, Hineno S, Matsunaga K, et al. Mutant idh1 dysregulates the differentiation of mesenchymal stem cells in association with gene-specific histone modifications to cartilage- and bone-related genes. PLoS One. 2015;10:1\u201315.","journal-title":"PLoS One"},{"key":"1227_CR85","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474\u20138.","journal-title":"Nature"},{"key":"1227_CR86","doi-asserted-by":"publisher","first-page":"eabh3243","DOI":"10.1126\/sciadv.abh3243","volume":"7","author":"MS Alghamri","year":"2021","unstructured":"Alghamri MS, McClellan BL, Avvari RP, Thalla R, Carney S, Hartlage MS, et al. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci Adv. 2021;7:eabh3243.","journal-title":"Sci Adv"},{"key":"1227_CR87","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","volume":"2","author":"M Friedrich","year":"2021","unstructured":"Friedrich M, Sankowski R, Bunse L, Kilian M, Green E, Ramallo Guevara C, et al. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nat Cancer. 2021;2:723\u201340.","journal-title":"Nat Cancer"},{"key":"1227_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01175-6","volume":"15","author":"Y Wei","year":"2023","unstructured":"Wei Y, Li G, Feng J, Wu F, Zhao Z, Bao Z, et al. Stalled oligodendrocyte differentiation in IDH-mutant gliomas. Genome Med. 2023;15:24.","journal-title":"Genome Med"},{"key":"1227_CR89","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ccell.2020.07.008","volume":"38","author":"C Chung","year":"2020","unstructured":"Chung C, Sweha SR, Pratt D, Tamrazi B, Panwalkar P, Banda A, et al. Integrated metabolic and epigenomic reprograming by H3K27M mutations in diffuse intrinsic pontine gliomas. Cancer Cell. 2020;38:334\u2013349.e9.","journal-title":"Cancer Cell"},{"key":"1227_CR90","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nm.4293","volume":"23","author":"F Mohammad","year":"2017","unstructured":"Mohammad F, Weissmann S, Leblanc B, Pandey DP, H\u00f8jfeldt JW, Comet I, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med. 2017;23:483\u201392.","journal-title":"Nat Med"},{"key":"1227_CR91","doi-asserted-by":"publisher","first-page":"27087","DOI":"10.18632\/oncotarget.25484","volume":"9","author":"H Feng","year":"2018","unstructured":"Feng H, Tillman H, Wu G, Davidoff AM, Yang J. Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines. Oncotarget. 2018;9:27087\u201391.","journal-title":"Oncotarget"},{"key":"1227_CR92","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00401-010-0767-x","volume":"120","author":"BC Mobley","year":"2010","unstructured":"Mobley BC, McKenney JK, Bangs CD, Callahan K, Yeom KW, Schneppenheim R, et al. Loss of SMARCB1\/INI1 expression in poorly differentiated chordomas. Acta Neuropathol. 2010;120:745\u201353.","journal-title":"Acta Neuropathol"},{"key":"1227_CR93","doi-asserted-by":"crossref","unstructured":"Koelsche C, Schrimpf D, Tharun L, Roth E, Sturm D, Jones DTW, et al. Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. Clin Sarcoma Res. 2017;7:9.","DOI":"10.1186\/s13569-017-0075-5"},{"key":"1227_CR94","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/path.6048","volume":"259","author":"N Karthik","year":"2023","unstructured":"Karthik N, Lee JJH, Soon JLJ, Chiu HY, Loh AHP, Ong DST, et al. Histone variant H3.3 promotes metastasis in alveolar rhabdomyosarcoma. J Pathol. 2023;259:342\u201356.","journal-title":"J Pathol"},{"key":"1227_CR95","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-022-00393-3","volume":"8","author":"F Cidre-Aranaz","year":"2022","unstructured":"Cidre-Aranaz F, Watson S, Amatruda JF, Nakamura T, Delattre O, de Alava E, et al. Small round cell sarcomas. Nat Rev Dis Prim. 2022;8:66.","journal-title":"Nat Rev Dis Prim"},{"key":"1227_CR96","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","volume":"13","author":"I Cortes-Ciriano","year":"2023","unstructured":"Cortes-Ciriano I, Steele CD, Piculell K, Al-Ibraheemi A, Eulo V, Bui MM, et al. Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. Cancer Discov. 2023;13:654\u201371.","journal-title":"Cancer Discov"},{"key":"1227_CR97","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-genet-112618-043527","volume":"53","author":"S Alberti","year":"2019","unstructured":"Alberti S, Dormann D. Liquid-liquid phase separation in disease. Annu Rev Genet. 2019;53:171\u201394.","journal-title":"Annu Rev Genet"},{"key":"1227_CR98","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.cell.2018.06.006","volume":"174","author":"J Wang","year":"2018","unstructured":"Wang J, Choi JM, Holehouse AS, Lee HO, Zhang X, Jahnel M, et al. A molecular grammar governing the driving forces for phase separation of prion-like RNA binding proteins. Cell. 2018;174:688\u2013699.e16.","journal-title":"Cell"},{"key":"1227_CR99","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.semcdb.2018.07.001","volume":"90","author":"IA Sawyer","year":"2019","unstructured":"Sawyer IA, Bartek J, Dundr M. Phase separated microenvironments inside the cell nucleus are linked to disease and regulate epigenetic state, transcription and RNA processing. Semin Cell Dev Biol. 2019;90:94\u2013103.","journal-title":"Semin Cell Dev Biol"},{"key":"1227_CR100","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.celrep.2015.01.042","volume":"10","author":"EM Tomazou","year":"2015","unstructured":"Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Sch\u00f6negger A, Datlinger P, et al. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep. 2015;10:1082\u201395.","journal-title":"Cell Rep"},{"key":"1227_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21690-7","volume":"12","author":"L Zuo","year":"2021","unstructured":"Zuo L, Zhang G, Massett M, Cheng J, Guo Z, Wang L, et al. Loci-specific phase separation of FET fusion oncoproteins promotes gene transcription. Nat Commun. 2021;12:1491.","journal-title":"Nat Commun"},{"key":"1227_CR102","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cell.2017.07.036","volume":"171","author":"G Boulay","year":"2017","unstructured":"Boulay G, Sandoval GJ, Riggi N, Iyer S, Buisson R, Naigles B, et al. Cancer-specific retargeting of BAF complexes by a prion-like domain. Cell. 2017;171:163\u2013178.e19.","journal-title":"Cell"},{"key":"1227_CR103","doi-asserted-by":"publisher","first-page":"100892","DOI":"10.1016\/j.cossms.2020.100892","volume":"25","author":"H Reed","year":"2021","unstructured":"Reed H, Kegui W, Yingxiao W, Qin P. Phase separation and histone epigenetics in genome regulation. Curr Opin Solid State Mater Sci. 2021;25:100892.","journal-title":"Curr Opin Solid State Mater Sci"},{"key":"1227_CR104","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1128\/MCB.00949-07","volume":"28","author":"X Ren","year":"2008","unstructured":"Ren X, Vincenz C, Kerppola TK. Changes in the distributions and dynamics of polycomb repressive complexes during embryonic stem cell differentiation. Mol Cell Biol. 2008;28:2884\u201395.","journal-title":"Mol Cell Biol"},{"key":"1227_CR105","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1074\/jbc.RA118.006620","volume":"294","author":"R Tatavosian","year":"2019","unstructured":"Tatavosian R, Kent S, Brown K, Yao T, Duc HN, Huynh TN, et al. Nuclear condensates of the Polycomb protein chromobox 2 (CBX2) assemble through phase separation. J Biol Chem. 2019;294:1451\u201363.","journal-title":"J Biol Chem"},{"key":"1227_CR106","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/ijc.28440","volume":"134","author":"B Dewaele","year":"2014","unstructured":"Dewaele B, Przybyl J, Quattrone A, Finalet Ferreiro J, Vanspauwen V, Geerdens E, et al. Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer. 2014;134:1112\u201322.","journal-title":"Int J Cancer"},{"key":"1227_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-11800-x","volume":"10","author":"R Ragazzini","year":"2019","unstructured":"Ragazzini R, P\u00e9rez-Palacios R, Baymaz IH, Diop S, Ancelin K, Zielinski D, et al. EZHIP constrains Polycomb Repressive Complex 2 activity in germ cells. Nat Commun. 2019;10:1\u201318.","journal-title":"Nat Commun"},{"key":"1227_CR108","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMra1805035","volume":"383","author":"SE Bates","year":"2020","unstructured":"Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383:650\u201363.","journal-title":"N Engl J Med"},{"key":"1227_CR109","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s43018-022-00403-z","volume":"3","author":"FPB Dubois","year":"2022","unstructured":"Dubois FPB, Shapira O, Greenwald NF, Zack T, Wala J, Tsai JW, et al. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat Cancer. 2022;3:994\u20131011.","journal-title":"Nat Cancer"},{"key":"1227_CR110","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrg3413","volume":"14","author":"JL Ronan","year":"2013","unstructured":"Ronan JL, Wu W, Crabtree GR. From neural development to cognition: Unexpected roles for chromatin. Nat Rev Genet. 2013;14:347\u201359.","journal-title":"Nat Rev Genet"},{"key":"1227_CR111","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1101\/gr.190629.115","volume":"25","author":"HT Bjornsson","year":"2015","unstructured":"Bjornsson HT. The Mendelian disorders of the epigenetic machinery. Genome Res. 2015;25:1473\u201381.","journal-title":"Genome Res"},{"key":"1227_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/dvg.23507","volume":"61","author":"K Bush","year":"2023","unstructured":"Bush K, Cervantes V, Yee JQ, Klein RH, Knoepfler PS. A knockout-first model of H3f3a gene targeting leads to developmental lethality. Genesis. 2023;61:1\u201310.","journal-title":"Genesis"},{"key":"1227_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abc9207","volume":"6","author":"L Bryant","year":"2020","unstructured":"Bryant L, Li D, Cox SG, Marchione D, Joiner EF, Wilson K, et al. Histone H3.3 beyond cancer: germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients. Sci Adv. 2020;6:1\u201312.","journal-title":"Sci Adv"},{"key":"1227_CR114","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/ng.3956","volume":"49","author":"F Tessadori","year":"2017","unstructured":"Tessadori F, Giltay JC, Hurst JA, Massink MP, Duran K, Vos HR, et al. Germline mutations affecting the histone H4 core cause a developmental syndrome by altering DNA damage response and cell cycle control. Nat Genet. 2017;49:1642\u20136.","journal-title":"Nat Genet"},{"key":"1227_CR115","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-15-1841","volume":"22","author":"RA Toledo","year":"2016","unstructured":"Toledo RA, Qin Y, Cheng ZM, Gao Q, Iwata S, Silva GM, et al. Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas. Clin Cancer Res. 2016;22:2301\u201310.","journal-title":"Clin Cancer Res"},{"key":"1227_CR116","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/leu.2016.364","volume":"31","author":"HP Koeffler","year":"2017","unstructured":"Koeffler HP, Leong G. Preleukemia: one name, many meanings. Leukemia. 2017;31:534\u201342.","journal-title":"Leukemia"},{"key":"1227_CR117","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424\u201333.","journal-title":"N Engl J Med"},{"key":"1227_CR118","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","volume":"26","author":"PA Marks","year":"2007","unstructured":"Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26:1351\u20136.","journal-title":"Oncogene"},{"key":"1227_CR119","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","volume":"45","author":"C Kadoch","year":"2013","unstructured":"Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45:592\u2013601.","journal-title":"Nat Genet"},{"key":"1227_CR120","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1038\/s41388-021-01781-x","volume":"40","author":"M Wanior","year":"2021","unstructured":"Wanior M, Kr\u00e4mer A, Knapp S, Joerger AC. Exploiting vulnerabilities of SWI\/SNF chromatin remodelling complexes for cancer therapy. Oncogene. 2021;40:3637\u201354.","journal-title":"Oncogene"},{"key":"1227_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: From biological insights to therapeutic potential. Biomark Res. 2018;6:1\u201310.","journal-title":"Biomark Res"},{"key":"1227_CR122","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","volume":"117","author":"DB Yap","year":"2011","unstructured":"Yap DB, Chu J, Berg T, Schapira M, Cheng SWG, Moradian A, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011;117:2451\u20139.","journal-title":"Blood"},{"key":"1227_CR123","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1101\/gad.186411.111","volume":"26","author":"C Simon","year":"2012","unstructured":"Simon C, Chagraoui J, Krosl J, Gendron P, Wilhelm B, Lemieux S, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 2012;26:651\u20136.","journal-title":"Genes Dev"},{"key":"1227_CR124","doi-asserted-by":"publisher","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","volume":"357","author":"WA Flavahan","year":"2017","unstructured":"Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357:eaal2380.","journal-title":"Science"},{"key":"1227_CR125","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrm.2016.166","volume":"18","author":"M Buschbeck","year":"2017","unstructured":"Buschbeck M, Hake SB. Variants of core histones and their roles in cell fate decisions, development and cancer. Nat Rev Mol Cell Biol. 2017;18:299\u2013314.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1227_CR126","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrm.2016.148","volume":"18","author":"PB Talbert","year":"2017","unstructured":"Talbert PB, Henikoff S. Histone variants on the move: substrates for chromatin dynamics. Nat Rev Mol Cell Biol. 2017;18:115\u201326.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1227_CR127","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrg3673","volume":"15","author":"I Maze","year":"2014","unstructured":"Maze I, Noh KM, Soshnev AA, Allis CD. Every amino acid matters: essential contributions of histone variants to mammalian development and disease. Nat Rev Genet. 2014;15:259\u201371.","journal-title":"Nat Rev Genet"},{"key":"1227_CR128","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev-genet-120417-031547","volume":"52","author":"P Grover","year":"2018","unstructured":"Grover P, Asa JS, Campos EI. H3\u2013H4 histone chaperone pathways. Annu Rev Genet. 2018;52:109\u201330.","journal-title":"Annu Rev Genet"},{"key":"1227_CR129","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cell.2013.08.061","volume":"155","author":"LA Banaszynski","year":"2013","unstructured":"Banaszynski LA, Wen D, Dewell S, Whitcomb SJ, Lin M, Diaz N, et al. Hira-dependent histone H3.3 deposition facilitates PRC2 recruitment at developmental loci in ES cells. Cell. 2013;155:107\u201320.","journal-title":"Cell"},{"key":"1227_CR130","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1101\/sqb.2010.75.008","volume":"75","author":"SJ Elsaesser","year":"2010","unstructured":"Elsaesser SJ, Allis CD. HIRA and Daxx constitute two independent histone H3.3-containing predeposition complexes. Cold Spring Harb Symp Quant Biol. 2010;75:27\u201334.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"1227_CR131","doi-asserted-by":"publisher","first-page":"14075","DOI":"10.1073\/pnas.1008850107","volume":"107","author":"PW Lewis","year":"2010","unstructured":"Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci USA. 2010;107:14075\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1227_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01206-y","volume":"8","author":"D Hoelper","year":"2017","unstructured":"Hoelper D, Huang H, Jain AY, Patel DJ, Lewis PW. Structural and mechanistic insights into ATRX-dependent and -independent functions of the histone chaperone DAXX. Nat Commun. 2017;8:1193.","journal-title":"Nat Commun"},{"key":"1227_CR133","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.cell.2010.01.003","volume":"140","author":"AD Goldberg","year":"2010","unstructured":"Goldberg AD, Banaszynski LA, Noh K, Lewis PW, Elsaesser SJ, Stadler S, et al. Distinct factors control histone at specific genomic regions. Cell. 2010;140:678\u201391.","journal-title":"Cell"},{"key":"1227_CR134","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.celrep.2015.03.036","volume":"11","author":"HPJ Voon","year":"2015","unstructured":"Voon HPJ, Hughes JR, Rode C, DeLaRosa-Vel\u00e1zquez IA, Jenuwein T, Feil R, et al. ATRX plays a key role in maintaining silencing at interstitial heterochromatic loci and imprinted genes. Cell Rep. 2015;11:405\u201318.","journal-title":"Cell Rep"},{"key":"1227_CR135","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature14345","volume":"522","author":"SJ Els\u00e4sser","year":"2015","unstructured":"Els\u00e4sser SJ, Noh KM, Diaz N, Allis CD, Banaszynski LA. Histone H3.3 is required for endogenous retroviral element silencing in embryonic stem cells. Nature. 2015;522:240\u20134.","journal-title":"Nature"},{"key":"1227_CR136","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cell.2013.08.029","volume":"155","author":"S Adam","year":"2013","unstructured":"Adam S, Polo SE, Almouzni G. Transcription recovery after DNA damage requires chromatin priming by the H3.3 histone chaperone HIRA. Cell. 2013;155:94.","journal-title":"Cell"},{"key":"1227_CR137","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41586-020-2533-0","volume":"583","author":"A Armache","year":"2020","unstructured":"Armache A, Yang S, Mart\u00ednez de Paz A, Robbins LE, Durmaz C, Cheong JQ, et al. Histone H3.3 phosphorylation amplifies stimulation-induced transcription. Nature. 2020;583:852\u20137.","journal-title":"Nature"},{"key":"1227_CR138","doi-asserted-by":"publisher","first-page":"12562","DOI":"10.1073\/pnas.1608270113","volume":"113","author":"AE Lepack","year":"2016","unstructured":"Lepack AE, Bagot RC, Pe\u00f1a CJ, Loh YE, Farrelly LA, Lu Y. Aberrant H3.3 dynamics in NAc promote vulnerability to depressive-like behavior. Proc Natl Acad Sci USA. 2016;113:12562\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1227_CR139","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neuron.2015.06.014","volume":"87","author":"I Maze","year":"2015","unstructured":"Maze I, Wenderski W, Noh KM, Bagot RC, Tzavaras N, Purushothaman I, et al. Critical role of histone turnover in neuronal transcription and plasticity. Neuron. 2015;87:77\u201394.","journal-title":"Neuron"},{"key":"1227_CR140","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neuron.2012.02.021","volume":"74","author":"D Michod","year":"2012","unstructured":"Michod D, Bartesaghi S, Khelifi A, Bellodi C, Berliocchi L, Nicotera P, et al. Calcium-dependent dephosphorylation of the histone chaperone DAXX regulates H3.3 loading and transcription upon neuronal activation. Neuron. 2012;74:122\u201335.","journal-title":"Neuron"},{"key":"1227_CR141","doi-asserted-by":"publisher","first-page":"602","DOI":"10.18632\/aging.101194","volume":"9","author":"D Bano","year":"2017","unstructured":"Bano D, Piazzesi A, Salomoni P, Nicotera P. The histone variant H3.3 claims its place in the crowded scene of epigenetics. Aging (Albany NY). 2017;9:602\u201314.","journal-title":"Aging (Albany NY)"},{"key":"1227_CR142","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.celrep.2016.09.074","volume":"17","author":"A Piazzesi","year":"2016","unstructured":"Piazzesi A, Papi\u0107 D, Bertan F, Salomoni P, Nicotera P, Bano D. Replication-independent histone variant H3.3 controls animal lifespan through the regulation of pro-longevity transcriptional programs. Cell Rep. 2016;17:987\u201396.","journal-title":"Cell Rep"},{"key":"1227_CR143","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.bbagrm.2015.09.008","volume":"1859","author":"P Scaffidi","year":"2016","unstructured":"Scaffidi P. Histone H1 alterations in cancer. Biochim Biophys Acta. 2016;1859:533\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"1227_CR144","first-page":"10007","volume":"46","author":"Y Arimura","year":"2018","unstructured":"Arimura Y, Ikura M, Fujita R, Noda M, Kobayashi W, Horikoshi N, et al. Cancer-associated mutations of histones H2B, H3.1 and H2A.Z.1 affect the structure and stability of the nucleosome. Nucleic Acids Res. 2018;46:10007\u201318.","journal-title":"Nucleic Acids Res"},{"key":"1227_CR145","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/2159-8290.CD-19-0393","volume":"9","author":"RL Bennett","year":"2019","unstructured":"Bennett RL, Bele A, Small EC, Will CM, Nabet B, Oyer JA, et al. A mutation in histone H2B represents a new class of oncogenic driver. Cancer Discov. 2019;9:1438\u201351.","journal-title":"Cancer Discov"},{"key":"1227_CR146","doi-asserted-by":"publisher","first-page":"12238","DOI":"10.1073\/pnas.1614120113","volume":"113","author":"S Zhao","year":"2016","unstructured":"Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, et al. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci USA. 2016;113:12238\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1227_CR147","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-020-0131-0","volume":"5","author":"YCE Wan","year":"2020","unstructured":"Wan YCE, Leung TCS, Ding D, Sun X, Liu J, Zhu L, et al. Cancer-associated histone mutation H2BG53D disrupts DNA\u2013histone octamer interaction and promotes oncogenic phenotypes. Signal Transduct Target Ther. 2020;5:27.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-023-01227-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-023-01227-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-023-01227-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T09:29:37Z","timestamp":1737106177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-023-01227-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1038\/s41418-023-01227-9","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}